Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

Healthcare company Organon & Co. (OGN) said on Wednesday that it is discontinuing the development of its investigational ...

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

Organon said on Wednesday it will the stop development of an experimental treatment it acquired through its purchase of Forendo Pharma, after the drug failed to reduce pelvic pain in women with ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

A new study from Karolinska Institutet involving over a million women links difficult childhood experiences to the risk of ...

Four in five people living with chronic pain are hiding their condition – held back by stigma, ineffective treatments, and ...

Organon (NYSE:OGN) stock is in focus as the company halts OG-6219 development after a Phase 2 trial in endometriosis-related pain fails. Read more here.

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational candidate OG-6219 in ...

The Global Endometriosis Treatment Market is expected to reach at a CAGR of 10.62% during the forecast period 2025-2033. Sai Kiran DataM Intelligence 4Market Research +1 877-441-4866 ... Visit us on ...